Did you know that NIH can actually help pay off some of your educational debt? Up to $50,000 worth over two years in fact! Now that we have your attention, join us for this first in a two part NIH All About Grants podcast mini-series on the NIH Loan Repayment Programs (LRPs)…read on for more…
Looking for answers to your questions on our Early Stage Investigator (ESI) policy? Check out the following highlighted frequently asked questions (FAQ) for information on how NIH defines and reviews ESI applications to promote the growth and stability of the biomedical research workforce.
At NIH, we are heavily invested in our workforce and in understanding the barriers they face. What characteristics do they share? How do they compete in the current hypercompetitive environment? When do they stop applying to NIH (drop out), even after receiving their first award? Staff from the National Institute of Allergy and Infectious Diseases (NIAID) delve into these questions in a paper published recently in PLOS ONE , whose findings I’d like to highlight today. Here, Drs. Patricia Haggerty and Matthew Fenton looked at factors that may contribute to the success of early-career investigators and if these factors affect all junior researchers equally.
In earlier posts, like this one, we discussed the importance of moving towards “evidence-based funding.”. NIH seeks to apply data-driven strategies to conceptualize, develop, implement, and evaluate policies, such as those that will affect the NIH-supported biomedical research workforce. Today, we’d like to spotlight a recently published analysis of an award program directed to investigators early in their careers – a population that has received much attention at NIH and beyond in recent years.
As NIH continues its work to better understand the many factors that influence the stability of the biomedical workforce, we wanted to take a moment to discuss some recent papers that highlight the need to take new measures to support early and mid-career researchers.
We appreciate the many thoughtful comments posted to the blog about working together to improve NIH funding support for early- and mid-career investigators to stabilize the biomedical workforce and research enterprise using a measure called the Grant Support Index (GSI). Some clear themes have emerged, including: ….
While NIH policies focus on early stage investigators, we also recognize that it is in our interest to make sure that we continue to support outstanding scientists at all stages of their career. Many of us have heard mid-career investigators express concerns about difficulties staying funded. In a 2016 blog post we looked at data to answer the frequent question, “Is it more difficult to renew a grant than to get one in the first place?” We found that new investigators going for their first competitive renewal had lower success rates than established investigators. More recently, my colleagues in OER’s Statistical Analysis and Reporting Branch and the National Heart Lung and Blood Institute approached the concerns of mid-career investigators in a different way – by looking at the association of funding with age. Today I’d like to highlight some of the NIH-wide findings, recently published in the PLOS ONE article, “Shifting Demographics among Research Project Grant Awardees at the National Heart, Lung, and Blood Institute (NHLBI)”. Using age as a proxy for career stage, the authors analyzed funding outcomes for three groups ….
When applicants receive their summary statement resulting from the review of an application that was assigned a score outside of the ICs funding range, there are important decisions to be made that, ideally, should be based upon evidence. What is the likelihood that an application like this one will be funded? If I resubmit the application, what changes might improve the chances for a successful resubmission?
Recall that in 2014, NIH relaxed its resubmission policy (OD-14-074) to allow applicants to submit a new (A0) application following an unsuccessful resubmission application. Also, we recently posted a piece showing that review outcomes for new applications submitted following an unsuccessful resubmission had about the same funding success as other new applications. But some applicants may wonder, what is the funding success for a resubmission application? ….
The strength of the biomedical research enterprise depends on new researchers becoming independent NIH-funded researchers, bringing fresh ideas and perspectives for solving scientific questions. As we have discussed here and in other venues, we are keenly aware that the long training period, aging of the biomedical workforce, and the fiscally challenging times all impact the ability of individuals to move from training positions into independent research positions. ….
